Psychedelics Fast-Tracked: What This Actually Means (and Why It Matters)

This week, President Trump signed an executive order aimed at accelerating the research and potential approval of psychedelic therapies. It’s the kind of headline that can easily get flattened into something overly simple—psychedelics are being fast-tracked—but what’s actually happening is more nuanced than that, and in many ways more meaningful.

This isn’t just about speed. It reflects a broader shift in how these treatments are being understood—moving from the shadows of medicine toward something that is being taken more seriously at a federal level. For those of us who have been watching this space evolve, it feels less like a sudden change and more like a continuation of something that has been building for years. That shift is something I’m already seeing reflected in conversations with clients here in Sedona, where interest in psychedelic-assisted therapy continues to grow alongside a desire for deeper, more integrative approaches to healing.

What the order is actually doing

At a practical level, the order directs agencies like the U.S. Food and Drug Administration to prioritize and accelerate the review of psychedelic compounds, including psilocybin, MDMA, LSD, and ibogaine. Given how slow and restrictive this process has historically been, that alone is significant.

There are a few important elements embedded in this. The order emphasizes expanded funding for research, particularly for veterans with PTSD and traumatic brain injury—an area where advocacy has been especially strong. It also signals a willingness to revisit federal scheduling classifications, which have long labeled these substances as having no accepted medical use and, in doing so, have made research far more difficult than it needs to be. In addition, there is support for expanded access pathways, meaning that individuals with severe or treatment-resistant conditions may, in some cases, be able to access therapies that are still in the clinical trial phase.

Taken together, this is not legalization or deregulation. It is better understood as an effort to reduce friction in a system that has historically made this kind of work difficult to study, let alone implement.

What this changes—and what it doesn’t

It’s important to ground this moment, because it’s easy for momentum like this to get ahead of reality. Psychedelics are not suddenly legal or widely available, and clinicians are not now free to offer these treatments outside of approved frameworks. The need for careful, well-designed clinical trials remains very much in place.

What does change is the pace and, perhaps more importantly, the level of support. We’re likely to see faster movement through research phases, increased federal investment, and growing pressure on regulatory bodies to make decisions more efficiently. In some cases, this may translate into earlier access for individuals who are not finding relief through existing treatments. In that sense, the conversation begins to shift from if these therapies will enter broader clinical use to how that process will unfold and who will benefit from it.

Why this matters for trauma

From a clinical perspective, this is where the relevance becomes clear. If you’ve worked with trauma long enough, you begin to notice that insight is rarely the primary issue. Many clients understand their histories in depth. They can articulate what happened, recognize patterns, and even anticipate their reactions, yet the nervous system often remains unchanged—cycling through fear, hypervigilance, or shutdown in ways that don’t easily shift.

This is where psychedelic-assisted therapies have shown particular promise. Compounds like MDMA and psilocybin appear to modulate fear responses and increase emotional openness, allowing individuals to engage with traumatic material differently. Rather than pushing harder against defenses, these approaches seem to create enough internal safety for people to approach experiences that have previously felt overwhelming or inaccessible. For individuals seeking trauma therapy in Sedona or more immersive healing environments, this emerging model is part of a broader shift toward treatments that integrate mind, body, and lived experience more directly.

Eating disorders: where this becomes relevant

This is the area where, clinically, I feel a particular sense of hope. Eating disorders are often misunderstood as being primarily about food, when in reality they are deeply connected to identity, control, shame, and protection. The patterns are not only behavioral; they are structural—woven into how someone understands themselves and navigates the world.

We often see a kind of rigidity in these presentations, organized around beliefs such as:

• This is how I stay safe

• This is who I am

• If I let go of this, something worse will happen

These beliefs are not easily shifted, even when they are causing significant harm. Traditional therapies can be incredibly effective, but there are individuals who continue to feel stuck despite genuine effort and insight.

What psychedelic-assisted therapy may offer is not a direct solution, but a temporary loosening of that rigidity. In early research and clinical work, we’re seeing increased flexibility—both cognitively and emotionally—along with moments of self-compassion where there was previously only self-criticism. Those moments don’t resolve the disorder on their own, but they can create an opening, and for some individuals, that opening represents the first meaningful shift in a long time. This is part of why there is growing interest in psychedelic-informed approaches to eating disorder treatment, including here in Sedona, where psychospiritual and integrative models of care are already part of the therapeutic landscape.

Holding both excitement and responsibility

There is real reason for optimism here. Federal support has a way of legitimizing a field, reducing stigma, and opening the door for more robust research and training. At the same time, it’s important not to lose sight of the complexity of this work.

Psychedelic therapy is not simply about the medicine itself. It requires careful screening to determine appropriateness, thoughtful preparation to establish safety and intention, skilled facilitation during the experience, and meaningful integration afterward. Without these elements, the same experiences that can be healing may also become confusing or destabilizing. As interest grows in places like Sedona—where many people are already seeking deeper healing experiences—the importance of doing this work in a grounded, clinically responsible way becomes even more essential.

Where this leaves us

This executive order doesn’t mark the arrival of psychedelic therapy into mainstream care, but it does reflect a meaningful shift in direction. It signals a movement away from dismissal and toward engagement, and from rigid prohibition toward cautious exploration.

For individuals living with trauma, eating disorders, or other treatment-resistant conditions, that shift matters. Not as a guarantee, but as a widening of what may be possible—and sometimes, that widening is where change begins.

For those here who feel drawn to this work, there’s space to explore what it might look like in a thoughtful and grounded way. Sometimes curiosity is simply a place to begin. If that applies to you, please feel free to reach out.

Want to learn more about Psychedelics? click here.